Fractyl Health
- Total Funding$190.1 M
OverviewSuggest Edit
Fractyl Health (formerly known as Fractyl Laboratories) is a company developing solutions for the treatment of chronic diseases. It is engaged in the development of a minimally invasive procedural therapy that can reverse metabolic diseases. In addition, it offers Revita DMR technology for patients with type 2 diabetes.
| Type | Private | |
| Founded | 2010 | |
| HQ | Lexington, MA, US | Map |
| Website | fractyl.com |
Latest Updates
| Employees (est.) (Jun 2022) | 86 | (-1%) |
| Cybersecurity rating | B | More |
Key People/Management at Fractyl Health
Harith Rajagopalan
Co-Founder, Chief Executive Officer
Jay Caplan
Co-Founder, President
Lisa Davidson
Chief Financial Officer
Juan Carlos Lopez-Talavera
Chief Medical Officer
Jonathan Fitzgerald
Vice President, Regulatory Affairs and Quality Assurance
Len Rosberg
Vice President of Manufacturing
Fractyl Health Office Locations
Fractyl Health has an office in Lexington
Lexington, MA, US (HQ)
17 Hartwell Avenue
Fractyl Health Financials and Metrics
Summary Metrics
Founding Date | 2010 |
Fractyl Health total Funding | $190.1 m |
Fractyl Health latest funding size | $55 m |
Time since last funding | 2 years ago |
Fractyl Health investors | True Ventures, Bessemer Venture Partners, General Catalyst, Mithril Capital Management, Emergent Medical Partners, Domain Associates, YJ Capital, Deerfield, GV, IDO Investments, iDo Fund, Taiwania Capital Management Corporation, Catalio Capital Management, CDIB Venture Capital |
Fractyl Health's latest funding round in August 2020 was reported to be $55 m. In total, Fractyl Health has raised $190.1 m
Fractyl Health Cybersecurity Score
Fractyl Health Online and Social Media Presence
Fractyl Health's Trends
Fractyl Health News and Updates
April 04, 2022
Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin
Revitalize-2 is the second pivotal study for the Revita DMR® system (Revita®) in Fractyl Health’s Revitalize T2D clinical development program Revitalize T2D is designed to evaluate the potential of Revita in over 1,000 patients across the spectrum of T2D and prediabetes LEXINGTON, MA., April 4, 20…
August 09, 2020
Taiwania Capital leads $55m Series E round in Fractyl Laboratories
The round was joined by existing investors including Bessemer Venture Partners, General Catalyst, Domain Associates and Mithril Capital Management.
The post Taiwania Capital leads $55m Series E round in Fractyl Laboratories appeared first on DealStreetAsia.
Fractyl Health Blogs
May 17, 2022
Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022
LEXINGTON, MA, May 17, 2022 – Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in Sa…
November 30, 2021
Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size
– Revitalize-1, formerly REVITA-T2Di, is the first new study in Fractyl Health’s Revitalize T2D clinical development program – – Revitalize T2D is designed to evaluate the potential of the Revita® DMR System in approximately 1,000 patients across the spectrum of type 2 diabetes and prediabetes – LEX…
October 27, 2021
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
-Publication represents paradigm shift in our understanding of metabolism and the gut’s role in obesity and metabolic disease- -We believe the Metabolic Balance Model holds promising clues for the future of metabolic disease modification- LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life…
September 01, 2021
Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita® DMR for Type 2 Diabetes
-REVITA-T2Di study is assessing potential of outpatient Revita DMR treatment to improve glycemic control and reduce or eliminate need for daily insulin – LEXINGTON, Mass., September 1, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at rev…
June 16, 2021
After a decade in the type 2 diabetes game, Fractyl Laboratories recharges with a fresh $100M and a new name
Read more
The post After a decade in the type 2 diabetes game, Fractyl Laboratories recharges with a fresh $100M and a new name appeared first on Fractyl.
June 16, 2021
Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes
Fractyl Health today announced the closing of a $100 million Series F financing. The financing was led by new investors Maverick Capital, M28 Capital, and Population Health Partners, with participation by other new and existing investors. As part of this financing, Marc Elia, founder of M28 Capital,…
Fractyl Health Frequently Asked Questions
When was Fractyl Health founded?
Fractyl Health was founded in 2010.
Who are Fractyl Health key executives?
Fractyl Health's key executives are Harith Rajagopalan, Jay Caplan and Lisa Davidson.
How many employees does Fractyl Health have?
Fractyl Health has 86 employees.
Who are Fractyl Health competitors?
Competitors of Fractyl Health include Auxulin Pharmaceuticals, BioGenCell and Viatris.
Where is Fractyl Health headquarters?
Fractyl Health headquarters is located at 17 Hartwell Avenue, Lexington.
Where are Fractyl Health offices?
Fractyl Health has an office in Lexington.
How many offices does Fractyl Health have?
Fractyl Health has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies